GC
LXRX icon

Globeflex Capital’s Lexicon Pharmaceuticals LXRX Stock Holding History

Globeflex Capital’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-28,667
Closed -$98K – 477
2020
Q4 		$98K Hold
28,667
– – 0.02% 417
2020
Q3 		$41K Hold
28,667
– – 0.01% 422
2020
Q2 		$57K Hold
28,667
– – 0.01% 441
2020
Q1 		$56K Buy
+28,667
New +$85.3K 0.02% 434

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Globeflex Capital's LXRX Position: Q1 2021 in Review

Globeflex Capital sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2021, closing a stake of 28,667 shares — an estimated $98K sold.

Globeflex Capital first reported a position in LXRX in Q1 2020 and held it in 4 quarters. The position peaked at $98K in Q4 2020. 107 funds tracked by Wall St. Rank hold LXRX as of Q1 2021.

  • Globeflex Capital reported no remaining Lexicon Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Globeflex Capital sold 28,667 Lexicon Pharmaceuticals shares in Q1 2021, an estimated $98K.
  • Globeflex Capital first reported a position in Lexicon Pharmaceuticals in Q1 2020 and held it in 4 quarters.
  • Globeflex Capital's Lexicon Pharmaceuticals position peaked at $98K in Q4 2020.
  • 107 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2021.

Based on Globeflex Capital's 13F filing for Q1 2021, filed 14 May 2021.